天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

KI16425

KI16425 Struktur
355025-24-0
CAS-Nr.
355025-24-0
Englisch Name:
KI16425
Synonyma:
CS-88;KI-6425;Debio 0719;Ki16425, >=98%;KI16425 USP/EP/BP;KI-16425; KI 16425;Ki16425 (Debio 0719);KI16425;KI-16425; KI 16425;Ki 16425, competitive, potent and reversible antagonist to LPA;Ki 16425, 98%, competitive, potent and reversible antagonist to LPA
CBNumber:
CB9497429
Summenformel:
C23H23ClN2O5S
Molgewicht:
474.96
MOL-Datei:
355025-24-0.mol

KI16425 Eigenschaften

Schmelzpunkt:
59.5-60.5 °C
Siedepunkt:
623.7±55.0 °C(Predicted)
Dichte
1.353
storage temp. 
-20°C
L?slichkeit
DMSO: 16 mg/mL
Aggregatzustand
solid
pka
4.32±0.10(Predicted)
Farbe
white

Sicherheit

Kennzeichnung gef?hrlicher Xi
R-S?tze: 36/37/38
S-S?tze: 26-36
WGK Germany  3
HS Code  29349990

KI16425 Chemische Eigenschaften,Einsatz,Produktion Methoden

R-S?tze Betriebsanweisung:

R36/37/38:Reizt die Augen, die Atmungsorgane und die Haut.

S-S?tze Betriebsanweisung:

S26:Bei Berührung mit den Augen sofort gründlich mit Wasser abspülen und Arzt konsultieren.
S36:DE: Bei der Arbeit geeignete Schutzkleidung tragen.

Beschreibung

Lysophosphatidic acid (LPA) is a bioactive lipid mediator that signals through five distinct G protein-coupled receptors (LPA1-5). Ki16425 is a LPA receptor antagonist with selectivity for LPA1 and LPA3. It exhibits Ki values of 0.34, 6.5, and 0.93 μM for the human LPA1, LPA2, and LPA3 receptors, respectively, as determined by measuring inositol phosphate production in RH7777-transfected cells. Ki1642, at 10 μM, significantly blocks the response of a variety of cancer cell lines to LPA-induced cell migration.

Verwenden

Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3.

Biochem/physiol Actions

Ki 16425 possesses a short-lived inhibitory activity. It has been studied that Ki 16425 is effective in the inhibition of neuropathic pain‐like behaviors.

KI16425 Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte


KI16425 Anbieter Lieferant Produzent Hersteller Vertrieb H?ndler.

Global( 107)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Capot Chemical Co.,Ltd.
+86-(0)57185586718 +86-13336195806
sales@capot.com China 29791 60
ATK CHEMICAL COMPANY LIMITED
+undefined-21-51877795
ivan@atkchemical.com China 32957 60
Biochempartner
0086-13720134139
candy@biochempartner.com CHINA 965 58
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28172 58
Alchem Pharmtech,Inc.
8485655694
sales@alchempharmtech.com United States 63687 58
CONIER CHEM AND PHARMA LIMITED
+8618523575427
sales@conier.com China 49374 58
TargetMol Chemicals Inc.
+1-781-999-5354 +1-00000000000
marketing@targetmol.com United States 32161 58
Dideu Industries Group Limited
+86-29-89586680 +86-15129568250
1026@dideu.com China 22784 58
Zhejiang J&C Biological Technology Co.,Limited
+1-2135480471 +1-2135480471
sales@sarms4muscle.com China 10473 58
InvivoChem
+1-708-310-1919 +1-13798911105
sales@invivochem.cn United States 6391 58

  • 3-[[[4-[4-[[[1-(2-chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazoly]phenyl]methyl]thio]-propanoic acid
  • 3-[[[4-[4-[[[1-(2-Chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazolyl]phenyl]methyl]thio]propanoic acid
  • KI-6425
  • 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonyl)-3-methylisoxazol-5-yl)benzylthio)propanoic acid
  • Ki16425, >=98%
  • KI16425;KI-16425; KI 16425
  • 3-[[4-[4-[1-(2-chlorophenyl)ethoxycarbonylamino]-3-methyl-isoxazol-5-yl]phenyl]methylsulfanyl]propanoic acid
  • 3-((4-(4-(((1-(2-Chlorophenyl)ethoxy)carbonyl)amino)-3-methylisoxazol-5-yl)benzyl)thio)propano
  • CS-88
  • KI-16425; KI 16425
  • Ki 16425, 98%, competitive, potent and reversible antagonist to LPA
  • Debio 0719
  • Propanoic acid, 3-[[[4-[4-[[[1-(2-chlorophenyl)ethoxy]carbonyl]amino]-3-methyl-5-isoxazolyl]phenyl]methyl]thio]-
  • KI16425 USP/EP/BP
  • Ki16425 (Debio 0719)
  • Ki 16425, competitive, potent and reversible antagonist to LPA
  • 355025-24-0
  • Inhibitors
Copyright 2019 ? ChemicalBook. All rights reserved